Medcool's RapidCool technology:
This article was originally published in Clinica
Executive Summary
Medcool has received US FDA 510(k) clearance to market its noninvasive RapidCool system for reducing head and body temperature where clinically indicated - eg in hyperthermic patients. The device uses a patented disposable helmet that directs agitated cold water to the scalp, plus standard body and neck pads to rapidly cool the head and body. It reduces temperature to a set point in the range of 32-37 degrees C, and does not interfere with other hospital procedures such as cardiac catheterisation. A growing body of research indicates that mild hypothermia, in the range of 32-34 degrees C, could have a protective effect, reducing damage from cardiac arrest, stroke, brain injury and other traumatic events, said the Wellesley, Massachusetts firm.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.